Jon Ellis
Director/Board Member presso Orchard Therapeutics (Europe) Ltd.
Profilo
Attualmente, Jon Ellis ricopre la posizione di vicepresidente e responsabile della scienza e della tecnologia alla GlaxoSmithKline Plc. È anche nel consiglio di amministrazione di Orchard Therapeutics (Europe) Ltd. e Orchard Therapeutics Plc. Il Dr. Ellis ha ricevuto un dottorato dall'Università di Cambridge, un MBA dall'Henley Management College e una laurea e un diploma di specializzazione dal Magdalene College.
Posizioni attive di Jon Ellis
Società | Posizione | Inizio |
---|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 02/08/2018 |
Precedenti posizioni note di Jon Ellis
Società | Posizione | Fine |
---|---|---|
GSK PLC | Chief Tech/Sci/R&D Officer | 01/08/2022 |
ORCHARD THERAPEUTICS PLC | Director/Board Member | 16/06/2021 |
Formazione di Jon Ellis
University of Cambridge | Doctorate Degree |
Henley Management College | Masters Business Admin |
Magdalene College | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GSK PLC | Health Technology |
Aziende private | 2 |
---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Jon Ellis